- In October 2024, OncoZenge AB announced its intention to partner with Pharmanovia for the commercialization of BupiZenge in Europe, the Middle East, and Northern Africa (the “EMENA region”). This intended agreement focuses on addressing oral mucositis pain, a common and debilitating side effect of cancer treatments, highlighting a commitment to improving patient quality of life in the region.
- In May 2024, Barkat Pharmaceutical Group Through its subsidiary Sobhan Oncology introduced five new anticancer and antifungal drugs, helping meet domestic demand and expand exports—marking them as the first oncology drug manufacturer in the Middle East region
